Immuron Ltd ADR Cash Flow Conversion Efficiency
Immuron Ltd ADR cash flow conversion efficiency. Based on the latest financial reports, Immuron Ltd ADR (IMRN) has a cash flow conversion efficiency ratio of -0.186x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-2.43 Million) by net assets ($13.06 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Immuron Ltd ADR (2001–2025)
Cash flow conversion efficiency of Immuron Ltd ADR from 2001 to 2025. This chart illustrates how Immuron Ltd ADR's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Immuron Ltd ADR share price for real-time trading data and today's change.
Immuron Ltd ADR Cash Flow Conversion Ratio Explained
Immuron Ltd ADR cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Immuron Ltd ADR Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Immuron Ltd ADR ranked by their cash flow conversion efficiency. Also see Immuron Ltd ADR (IMRN) market capitalisation for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Ambow Education Holding Ltd
NYSE MKT:AMBO
|
0.153x |
|
Rolling Optics Holding AB (publ)
ST:RO
|
-0.033x |
|
Techstep ASA
OL:TECH
|
0.098x |
|
Empiric Student Property Plc
LSE:ESP
|
-0.009x |
|
Sewon E&C
KO:091090
|
-0.052x |
|
Masonglory Limited Ordinary Shares
NASDAQ:MSGY
|
-0.239x |
|
Future Metals NL
AU:FME
|
-0.069x |
|
Chia Yi Steel Co Ltd
TWO:2067
|
-0.113x |
Annual Cash Flow Conversion Efficiency for Immuron Ltd ADR (2001–2025)
The table below shows the annual cash flow conversion efficiency of Immuron Ltd ADR from 2001 to 2025. Review Immuron Ltd ADR financial flexibility index to assess the company's free cash flow relative to its total liabilities.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-06-30 | $8.03 Million | $-6.14 Million | -0.764x | -65.15% |
| 2024-06-30 | $12.71 Million | $-5.88 Million | -0.463x | -264.71% |
| 2023-06-30 | $19.62 Million | $-2.49 Million | -0.127x | +6.13% |
| 2022-06-30 | $23.18 Million | $-3.13 Million | -0.135x | -14.89% |
| 2021-06-30 | $25.90 Million | $-3.05 Million | -0.118x | +79.02% |
| 2020-06-30 | $5.64 Million | $-3.16 Million | -0.561x | -220.48% |
| 2019-06-30 | $7.35 Million | $-1.29 Million | -0.175x | +57.86% |
| 2018-06-30 | $8.44 Million | $-3.50 Million | -0.415x | +61.17% |
| 2017-06-30 | $6.57 Million | $-7.03 Million | -1.069x | -40.75% |
| 2016-06-30 | $4.94 Million | $-3.75 Million | -0.760x | -20.99% |
| 2015-06-30 | $4.81 Million | $-3.02 Million | -0.628x | -60.80% |
| 2014-06-30 | $6.79 Million | $-2.65 Million | -0.391x | +97.23% |
| 2013-06-30 | $144.99K | $-2.05 Million | -14.108x | -1074.35% |
| 2012-06-30 | $2.05 Million | $-2.46 Million | -1.201x | -5.67% |
| 2011-06-30 | $1.73 Million | $-1.97 Million | -1.137x | -69.19% |
| 2010-06-30 | $3.36 Million | $-2.26 Million | -0.672x | -105.99% |
| 2009-06-30 | $-184.87K | $-2.07 Million | 11.209x | +699.89% |
| 2008-06-30 | $1.11 Million | $-2.07 Million | -1.868x | -23.80% |
| 2007-06-30 | $1.98 Million | $-2.99 Million | -1.509x | -181.71% |
| 2006-06-30 | $5.24 Million | $-2.81 Million | -0.536x | -112.46% |
| 2005-06-30 | $6.96 Million | $-1.76 Million | -0.252x | +16.78% |
| 2004-06-30 | $4.08 Million | $-1.24 Million | -0.303x | +0.21% |
| 2002-06-30 | $6.32 Million | $-1.92 Million | -0.304x | -36.77% |
| 2001-06-30 | $7.48 Million | $-1.66 Million | -0.222x | -- |
About Immuron Ltd ADR
Immuron Limited, a biopharmaceutical company, engages in the research, development, and commercialization of polyclonal antibodies in Australia, the United States, and Canada. It operates through two segments, Research and Development; and Hyper-immune Products. The company offers Travelan, an over-the-counter medicine to reduce the risk of travelers' diarrhea and risk of minor gastrointestinal d… Read more